BIOMAT Database Logo BIOMAT Database Logo

Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist. 2020

Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Crinetics Pharmaceuticals, Inc., 10222 Barnes Canyon Road, San Diego, CA 92121, United States. Electronic address: jzhao@crinetics.com.

The discovery of a novel 3H-pyrido[2,3-d]pyrimidin-4-one series as potent and biased sst2 agonists is described. This class of molecules exhibits excellent sst2 potency and selectivity against sst1, sst3, and sst5 receptors, and they are significantly more potent at inhibiting cAMP production than inducing internalization. The orally bioavailable 6-(3-chloro-5-methylphenyl)-3-(3-fluoro-5-hydroxyphenyl)-5-({methyl[(2S)-pyrrolidin-2-ylmethyl]amino}methyl)-3H,4H-pyrido[2,3-d]pyrimidin-4-one (36) also suppresses GH secretion in GHRH-challenged rats in a dose-dependent manner.

UI MeSH Term Description Entries
D008297 Male Males
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists.
June 2007, Archiv der Pharmazie,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
May 2018, Bioorganic & medicinal chemistry letters,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Development of 2-aryl substituted quinazolin-4(3H)-one, pyrido[4,3-d]pyrimidin-4(3H)-one and pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as microsomal prostaglandin E(2) synthase-1 inhibitors.
October 2014, Bioorganic & medicinal chemistry letters,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Synthesis of new 2-substituted pyrido[2,3-d]pyrimidin-4(1H)-ones and their antibacterial activity.
March 2009, European journal of medicinal chemistry,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors.
February 2023, ACS medicinal chemistry letters,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
April 2005, Journal of medicinal chemistry,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
February 2021, European journal of medicinal chemistry,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Synthesis and pharmacological activity of 3-substituted pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-ones.
February 1984, Il Farmaco; edizione scientifica,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Anticancer Activity Evaluation of New Thieno[2,3-d]pyrimidin-4(3H)-ones and Thieno[3,2-d]pyrimidin-4(3H)-one Derivatives.
July 2018, Scientia pharmaceutica,
Jian Zhao, and Zhiyong Chen, and Ana Karin Kusnetzow, and Julie Nguyen, and Elizabeth Rico-Bautista, and Hannah Tan, and Stephen F Betz, and R Scott Struthers, and Yunfei Zhu
Synthesis and pharmacological study of antihyperlipaemic activity of 2-substituted thieno(2,3-d)pyrimidin-4(3H)-ones.
May 1990, Arzneimittel-Forschung,
Copied contents to your clipboard!